Effect of local mupirocin application on exit-site infection and peritonitis in an Indian peritoneal dialysis population.
BACKGROUND
Staphylococcus aureus-associated peritonitis and catheter exit-site infections (ESIs) are important causes of hospitalization and catheter loss in patients undergoing chronic peritoneal dialysis. Intranasal and topical use of mupirocin has been found to be an effective strategy in decreasing S. aureus-related infectious complications in persons who are carriers of S. aureus; however, there is no consensus regarding the prophylactic use of mupirocin irrespective of carrier status. We aimed to determine the potential effectiveness of application of mupirocin cream at the catheter exit site in preventing ESI and peritonitis irrespective of carrier status in a tropical country such as India.


METHODS
This prospective historically controlled study was done in a total of 40 patients. From August 2003, all patients, incident and prevalent, were instructed to apply 2% mupirocin cream daily to the exit site instead of the older practice of povidone-iodine and gauze dressing. Patients were not screened to determine whether they were S. aureus carriers. The infection-related data for 1 year, until July 2004, were compared with the historical control, which was infection-related data for the year preceding the year of mupirocin application.


RESULTS
Mean age of the study population was 62 years, with 61.8% being male and 64.3% being diabetic. Local application of mupirocin led to a significant reduction in the incidence density per patient-month of both ESI and peritonitis compared to controls (0.15 vs 0.37 and 0.37 vs 0.67, p = 0.01 for both). This amounted to a relative reduction of 60.5% and 55% respectively. ESI and peritonitis due to S. aureus were also significantly lower in the study group compared to controls (incidence density per patient-month 0.05 vs 0.13 and zero vs 0.17 respectively, p < 0.01 for both). There occurred no catheter removal due to infection-related complications during the study period compared to two during the control period. None of the patients reported a mupirocin-related adverse effect.


CONCLUSIONS
Daily application of mupirocin at the exit site is a well-tolerated and effective strategy in reducing the incidence of ESI and peritonitis in a tropical country such as India. It can thus significantly reduce morbidity, catheter loss, and transfer to hemodialysis in peritoneal dialysis patients.
Mahajan
Sandeep
S
Department of Nephrology, All India Institute of Medical Sciences, Ansari Nagar. mahajansn@yahoo.com
Tiwari
Suresh C
SC
Kalra
Vikram
V
Bhowmik
Dipankar M
DM
Agarwal
Sanjay K
SK
Dash
Suresh C
SC
Kumar
Parveen
P
D000287:Administration, Topical; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002408:Catheters, Indwelling; D005260:Female; D006801:Humans; D007194:India; D007674:Kidney Diseases / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016712:Mupirocin / Q000008:administration & dosage*; D010530:Peritoneal Dialysis; D010538:Peritonitis / Q000382:microbiology / Q000517:prevention & control*; D011446:Prospective Studies; D013203:Staphylococcal Infections / Q000517:prevention & control*
D000900:Anti-Bacterial Agents; D016712:Mupirocin